

# FOCUS ON TWO YEARS OF ECONOMIC OPINIONS ON SOLID CANCERS (2023-2024) - WHAT ARE THE SPECIFIC FEATURES VERSUS 2021-2022 ?



Bertrand T<sup>1</sup>, Georges A<sup>1</sup>, Sambuc C<sup>1</sup>.  
<sup>1</sup>VYOO AGENCY, 34 rue du Faubourg Saint Honoré, 75008 Paris

ISPOR EUROPE 2025  
9-12 NOVEMBER 2025 —  
GLASGOW, SCOTLAND, UK

### INTRODUCTION

In France, the Commission for Economic and Public Health Evaluation (CEESP) provides an economic opinion of the incremental cost-effectiveness ratio (ICER) validity.

Since 2016, due to the arrival of immunotherapies, treatment for solid tumor has taken a central position in marketing authorization and reimbursement. The many published opinions in this therapeutic area are likely to create anchoring and learning effects.

However, the eligibility criteria for an economic evaluation were revised by the HAS on June 23, 2022<sup>1,2</sup>. An exemption criterion was added, specifying that “when the request concerns an indication extension leading to an increase in the population reached by the product of less than 5% over two years.” This is likely to have an impact on the volume and type of economic dossiers submitted to the HAS concerning cancer treatments, given the access strategies.

### OBJECTIVE & METHODS


This study aims to analyze the CEESP opinions in oncology issued over the past two years (2023-2024) and to compare them with the findings of the previous analysis conducted by Vyoo in 2023 on CEESP assessments of solid tumor dossiers from 2021–2022.

Using **Vyoo Agency efficiency database**<sup>3</sup>, all CEESP opinions in oncology appraised between January 1<sup>st</sup>, 2021, and December 31<sup>st</sup>, 2024, were reviewed.

An opinion is considered valid if there is no mention of major global uncertainty or major reservation<sup>3</sup>.

## RESULTS

FIGURE 1. CANCER CATEGORIES (2021-2022 VS 2023-2024)




Over the two years, 10 CEESP opinions concerned drugs for solid tumor (-62% versus 2021-2022) on 5 different tumoral sites (versus 13 in 2021-2022).

FIGURE 2. EVOLUTION OF ICER (€ / QALY) ACROSS ASSESSMENT PERIODS



For those 10 dossiers, the average ICER is €163 985,94/ QALY (+8,4% versus 2021 -2022) and ranges from €29 342/ QALY to €355 002/QALY (-11,38% and +19,07% versus 2021-2022 respectively) and one opinion concluded that the drug is dominant.

FIGURE 3. CEESP ONCOLOGY EVALUATIONS BY TUMOR TYPE AND VALIDATION STATUS (2021-2022 VS 2023-2024)



### CONCLUSION

Over the two years considered for the analysis (2023-2024), CEESP has delivered 39 opinions, including 20 with a validated ICER (51%). Opinions on solid tumor comprised 25% of all opinions appraised during this period and they are characterized by a higher proportion of validated opinions (90%), compared with 2021-2022, CEESP oncology evaluations decreased substantially, but a higher proportion achieved validation, while ICER values remained stable overall.

This consistency in cost-effectiveness outcomes, despite fewer dossiers, suggests a shift toward more robust submissions and improved methodological alignment with CEESP expectations.

References  
1. Choices in methods for economic evaluation – HAS. 2020. [https://www.has-sante.fr/upload/docs/application/pdf/2020-11/methodological\\_guidance\\_2020\\_choices\\_in\\_methods\\_for\\_economic\\_evaluation.pdf](https://www.has-sante.fr/upload/docs/application/pdf/2020-11/methodological_guidance_2020_choices_in_methods_for_economic_evaluation.pdf).  
2. CEESP Doctrine. [https://www.has-sante.fr/upload/docs/application/pdf/2021-09/doctrine\\_de\\_la\\_ceesp.pdf](https://www.has-sante.fr/upload/docs/application/pdf/2021-09/doctrine_de_la_ceesp.pdf).  
3. Vyoo Agency efficiency database. Online subscription only: . <https://efficiency.vyoo-agency.com/>